Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
10:01am, Thursday, 05'th Mar 2026
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
South Africa seeks local production of Gilead's HIV prevention drug
01:02am, Thursday, 05'th Mar 2026
South Africa is asking local drugmakers to start a process to make Gilead Sciences' long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note
06:50pm, Tuesday, 03'rd Mar 2026
In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02:12pm, Tuesday, 03'rd Mar 2026
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
10:50am, Monday, 02'nd Mar 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US.
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
08:10am, Saturday, 28'th Feb 2026
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica
Weekend Morning Brew: Nvidia's Record, WBD Picks Paramount, OpenAI's $110B
07:37am, Saturday, 28'th Feb 2026
Weekly Market HighlightsMarket breadth was slightly positive with 4,817 advancers versus 4,692 decliners, but performance was highly skewed as the mean weekly
Gilead Sciences' Johanna Mercier on how she balances her energy
05:30pm, Friday, 27'th Feb 2026
CNBC's Julia Boorstin sits down with Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, who works to end HIV in our lifetime. Mercier explains how managing her energy he
Johanna Mercier on Gilead's HIV prevention innovation
02:30pm, Friday, 27'th Feb 2026
Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, discusses Gilead's groundbreaking HIV prevention innovation — a twice-yearly injection with 99.9% efficacy during th
Gilead's experimental HIV treatment shows low discontinuation rates in studies
02:27pm, Wednesday, 25'th Feb 2026
Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treat
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
10:09am, Wednesday, 25'th Feb 2026
Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash.
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
02:40pm, Tuesday, 24'th Feb 2026
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
First Look: Gilead buys Arcellx; IBM sinks on AI; Bitcoin slides
07:37am, Tuesday, 24'th Feb 2026
Stock News Dimon warns on credit cycle: JPMorgan Chase (JPM) CEO Jamie Dimon cautioned that elevated asset prices and growing banking competition echo preâ200
